One hundred forty-three institutions across 20 states posted opioid-related procurement requests in the last 60 days, roughly 3.7 times the prior 12-month bimonthly average of 38. In October 2026 alone, 39 states generated 174 opioid RFPs, with 79 of them explicitly naming "opioid settlement" as the funding source, about 10 times the typical monthly volume of settlement-specific solicitations from the year before. Nearly every one of these RFPs carries a "local funding" or "local and private funding" designation. This is not a federal grant surge. It is a spending deadline.
The trigger is the $7.4 billion Purdue Pharma/Sackler family settlement, which became legally effective May 1, 2026. On that date, the Sackler family paid $1.5 billion and Purdue paid approximately $900 million as the first installment, distributing roughly $2.4 billion to state and local governments in the first wave. All 55 attorneys general had signed on by June 2025. The money arrived. And then, in many jurisdictions, it sat.
A 2026 New Mexico state audit found that localities had spent only $15 million of $110 million received, a 14 percent utilization rate that auditors flagged as an under-deployment risk. New Mexico made it public. The lesson appears to have traveled. Under the national settlement framework, jurisdictions must formally justify any non-remediation use of funds and file utilization reports; the non-remediation use report deadline fell on September 30, 2026. Counties that had not yet encumbered their allocations to specific remediation-eligible programs, addiction treatment, early intervention, harm reduction, recovery support, faced scrutiny from settlement administrators at the start of Q4. The procurement wave that followed is a direct response.
The top states by institution count, Michigan (16), New Jersey (14), North Carolina (12), Washington (11), New York (10), and Massachusetts (10), are not simply the states with the largest opioid crises. They are states with well-organized county-level distribution frameworks that put money directly in local hands and then hold those hands accountable.
Michigan is the clearest case. The state's total settlement receipts are expected to reach $1.8 billion over the life of the agreements, with $800 million flowing to local governments. The Purdue/Sackler tranche alone adds $154 million to that pipeline, and a separate Remnant Defendants settlement, covering Associated Pharmacies and other smaller defendants, estimated at $720 million nationally, began accepting sign-ons in early 2026. Under Michigan's State-Subdivision Agreement, virtually every county receives its own discrete allocation and must file its own spending plan. The Michigan Association of Counties published updated spending and reporting guidance as recently as July 2026, and the effect appears in the data: county after county posted its own competitive RFP within weeks of each other, rather than routing funds through a single state agency.
North Carolina tells a similar story at larger scale. Attorney General Jeff Jackson has secured a cumulative $1.6 billion in settlement commitments for the state, with $1.3 billion directed to local governments, including roughly $150 million from the new Purdue/Sackler tranche. Wake County's allocation alone totals $67.7 million over 18 years, and the county has launched a visible cluster of RFPs covering early intervention, education, and outpatient addiction services. The state uses the CORE-NC platform to publish county-by-county spending transparency, which creates accountability pressure that accelerates procurement: when a county's balance is publicly visible and its neighbors are already posting RFPs, inaction is conspicuous.
New Jersey's 14 active institutions include both county sheriffs' offices and municipal public health agencies, suggesting that settlement dollars are flowing into law enforcement diversion programs alongside clinical services, a breadth of eligible use that the Exhibit E spending guidelines explicitly permit under harm reduction and recovery support categories.
It is worth being precise about what this surge is not. The active federal HHS and SAMHSA opioid grant portfolio across the top ten states totals approximately $3.9 billion, with California ($883 million), Pennsylvania ($766 million), and New York ($414 million) holding the largest shares. That federal infrastructure has been relatively stable year over year. The settlement RFPs are layering on top of it, not replacing it, and they operate under entirely different reporting chains, eligible recipients, and compliance requirements. A county health department managing a SAMHSA grant and a Purdue settlement allocation simultaneously is navigating two parallel compliance universes.
As of October 1, 2026, cumulative national opioid settlement allocations had reached $58.8 billion across all defendants, according to GrantFinder's Q4 2026 report, up from $57.7 billion just three months earlier, as the Remnant Defendants and other late-signing settlements continue to close. Payments are structured to continue into the late 2030s, but 2026 is the peak disbursement year for the Purdue tranche specifically, meaning the volume of new dollars hitting county accounts will not be this high again.
The next signal to watch is utilization reporting in early 2027. Settlement administrators will publish the first comprehensive accounting of how jurisdictions spent their 2026 allocations. States that generated high RFP volume this fall will show up as committed. Those that did not will face the same questions New Mexico's auditors asked, and those questions are now on the record.
